
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Anixa Biosciences Inc (ANIX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ANIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $9
1 Year Target Price $9
1 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.93% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 106.30M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 3 | Beta 0.33 | 52 Weeks Range 2.07 - 4.20 | Updated Date 06/30/2025 |
52 Weeks Range 2.07 - 4.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-06-06 | When - | Estimate -0.1 | Actual -0.09 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.75% | Return on Equity (TTM) -65.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 90276381 | Price to Sales(TTM) 481.54 |
Enterprise Value 90276381 | Price to Sales(TTM) 481.54 | ||
Enterprise Value to Revenue 368.98 | Enterprise Value to EBITDA -8.76 | Shares Outstanding 32211100 | Shares Floating 30497784 |
Shares Outstanding 32211100 | Shares Floating 30497784 | ||
Percent Insiders 5.32 | Percent Institutions 17.6 |
Analyst Ratings
Rating 2 | Target Price 9 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Anixa Biosciences Inc

Company Overview
History and Background
Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines that address critical unmet needs in oncology and infectious diseases. Founded in 2011, it has evolved from an early-stage company to one with several clinical-stage programs.
Core Business Areas
- Cancer Immunotherapy: Developing therapies that use the body's immune system to fight cancer. This includes a novel CAR-T therapy approach and a cancer vaccine technology.
- Infectious Disease Therapeutics: Focused on developing therapeutics for infectious diseases, including a potential treatment for COVID-19.
Leadership and Structure
The leadership team consists of individuals with experience in biotechnology, pharmaceuticals, and finance. The organizational structure is typical of a small biotech company, with research, development, and management functions.
Top Products and Market Share
Key Offerings
- CAR-T Therapy: Developing a novel CAR-T therapy that targets solid tumors. While not yet approved, if successful, it could address a significant unmet need in the treatment of solid tumors. Competitors include major pharmaceutical companies that are developing CAR-T therapies for hematological malignancies, such as Novartis and Gilead.
- Cancer Vaccine: Developing a vaccine to prevent certain cancers, initially focusing on triple-negative breast cancer. This program is in preclinical stages. The market share is currently 0%. Competitors include companies focused on cancer vaccines, such as Moderna and BioNTech.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high levels of innovation, intense competition, and regulatory scrutiny. There is growing demand for novel therapies, especially in oncology and infectious diseases.
Positioning
Anixa Biosciences is positioned as an innovative biotech company focused on developing novel therapies and vaccines. Its competitive advantage lies in its proprietary technologies and its focus on unmet medical needs.
Total Addressable Market (TAM)
The TAM for cancer immunotherapy and vaccines is estimated to be worth billions of dollars annually. Anixa's positioning aligns with capturing a segment of this large TAM through innovative solutions.
Upturn SWOT Analysis
Strengths
- Proprietary Technologies
- Focus on Unmet Medical Needs
- Experienced Management Team
- Pipeline of Clinical-Stage Programs
Weaknesses
- Limited Financial Resources
- Dependence on Clinical Trial Success
- Competition from Larger Companies
- Lack of Approved Products
Opportunities
- Positive Clinical Trial Results
- Partnerships with Larger Pharmaceutical Companies
- Expansion into New Therapeutic Areas
- Government Funding and Grants
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from New Therapies
- Economic Downturn
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- NVS
- GILD
Competitive Landscape
Anixa faces stiff competition from larger, more established pharmaceutical and biotechnology companies. Its advantages include its innovative technologies and focus on unmet medical needs. Its disadvantages include limited financial resources and lack of approved products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the pipeline and advancement of programs into clinical trials.
Future Projections: Future growth is dependent on positive clinical trial results and potential partnerships.
Recent Initiatives: Recent initiatives include advancing the CAR-T program and cancer vaccine into clinical development.
Summary
Anixa Biosciences is a development-stage biotechnology company with promising technology but limited resources. Its success is dependent on positive clinical trial results and the ability to secure partnerships or funding. Investors should be aware of the high level of risk associated with investing in development-stage biotech companies, but the potential returns could be substantial if Anixa's therapies are successful. They should look out for competition from big pharma and any negative regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Company Press Releases
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anixa Biosciences Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 1987-01-01 | CEO, Chairman & Co-Chair of CBAB Dr. Amit Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.anixa.com |
Full time employees 5 | Website https://www.anixa.com |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.